The goal of this study is to give a brief background on the literature supporting the
PharmGKB pathway about doxorubicin action, and provides a summary of this active area of
research. The reader is referred to recent in-depth reviews [1–4] for more detailed
discussion of this important and complex pathway. Doxorubicin is an anthracyline drug first
extracted from Streptomyces peucetius var. caesius in the 1970's and routinely used in the
treatment of several cancers including breast, lung, gastric, ovarian, thyroid, non-Hodgkin's …